Aligning ESCC and GI Cancer Treatment Strategies With Current Guidelines
A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.
Drivers of Health Resource Management in MDS
Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Challenges Surrounding Access to Care for Patients With MDS
Expert panelists explore challenges impacting care access for patients with MDS.
Improving Patient Access to Biosimilars
In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.
HUDSON Trial Overview and Key Takeaways
The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
Trajectory of Vitiligo Treatment Landscape
Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.
Payer Support for Emerging Vitiligo Treatments
The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.
Overview of CheckMate Trials 648 and 649
CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment.
KEYNOTE-590 Trial Impacting Treatment Landscape for ESCC and Upper GI Cancer
Syma Iqbal, MD, provides an overview of the KEYNOTE-590 trial and its impact on treatment pathways for ESCC and GI cancers.
Closing Thoughts on CKD Management
The esteemed panel concludes with their final thoughts on CKD therapies and management.
Continued Health Disparities Seen in Practice
Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.
Payer Considerations Impacted by Updated ATS Guidelines
Paul Noble, MD, provides his closing thoughts on payer perspectives surrounding ILD, as well as considerations for the trajectory of ILD treatment landscape.
Conditional Recommendation of Nintedanib and Use in ILD Treatment
Nintedanib recommendations for use from the recent ATS guidelines and treatment implementation are considered by Paul Noble, MD.
Prognostic Models Optimizing MDS Treatment Pathways
Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.
Incidence and Prevalence of MDS Across Patient Populations
Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.
Patient Engagement Strategies to Increase Biosimilar Uptake
Sonia Oskouei explores the managed care landscape and opportunities for increasing biosimilar uptake to improve patient care.
Evolving Treatment Landscape for Upper GI and Esophageal Cancer
Evolving treatment strategies for esophagogastric cancer are explored by Syma Iqbal, MD, including unmet needs across the treatment landscape.
Prevalence and Characteristics of GI Cancers
Syma Iqbal, MD, provides insights pertaining to various types of upper GI cancers, as well as primary characteristics and risk factors for these diseases.
Non-JAK Inhibitor Therapy Options Available for Vitiligo Treatment
Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.
Safety Considerations for Vitiligo-Focused Drug Therapies
Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.
Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment
Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
Combination Therapy and Payer Perspective on CKD Therapies
Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.
Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management
Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.
Utilizing Pirfenidone in ILD Treatment Strategy
Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.
FDA-Approved Treatment Options for ILD
ILD treatment options approved by the FDA are explored by Dr Noble, MD.
MDS Impacting Patient Quality of Life
Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Role of JAK Inhibitors in Treatment of Vitiligo
Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.
Unmet Needs in Vitiligo Treatment Landscape
The panel navigates unmet needs surrounding the vitiligo treatment landscape.
Identifying Unmet Needs Surrounding Patients With Heart Failure
The panel of experts provide their final insights regarding unmet needs surrounding treatment management of heart failure.
